458529-69-6

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 167834-23-3 ethyl (3S)-3-{[(tert-butoxy)carbonyl]amino}-3-phenylpropanoate 
• 3082-69-7 ethyl (3S)-3-amino-3-phenylpropionate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 528586-23-4 tert-butyl ((1S)-3-oxo-1-phenylbutyl)carbamate 
• 872001-88-2 C₁₆H₂₃NO₄ 
• 667402-23-5 (S)-[3-(4-{ethyl-[2-(4-methanesulfonylphenyl)-acetyl]-amino}-piperidin-1-yl)-1-phenyl-propyl]-carbamic acid 1',1',1'-trichloroethoxy ester hydrochloride 
• 667402-02-0 (S)-1-benzenesulfonyl-piperidine-4-carboxylic acid [3-(4-{ethyl-[2-(4-methanesulfonyl-phenyl)-acetyl]-amino}-piperidin-1-yl)-1-phenyl-propyl]-amide 
• 135865-78-0 tert-butyl (1S)-3-oxo-1-phenylpropylcarbamate 

Relevant academic research and scientific papers

1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV: Part 2

Optimisation of a series of 4-piperidinyltriazoles led to the identification of compound 28a which showed good whole cell antiviral activity, excellent selectivity over the hERG ion channel and complete oral absorption.

CHEMICAL COMPOUNDS

The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, Het and m are as defined in the description. The compounds of the present invention are modulators, especially antagonists, of the

TRIAZOLYLPIPERIDINE DERIVATIVES AND USE THEREOF IN THERAPY

The present invention provides compounds of formula (I) Wherein R1 , R2, R3 , R4 , Het and m are as defined in the description. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors.